Argireline dosage: reported doses and schedule
A topical cosmetic peptide with small, mixed wrinkle studies and limited skin penetration.
Also called: Acetyl hexapeptide-8, Acetyl hexapeptide-8 amide, Acetyl hexapeptide-3 (older name), AH8, Ac-EEMQRR-NH2.
Cosmetic peptides · SNAP-25-mimicking cosmetic hexapeptide.
Typical reported dose: Serum sold as 10% Argireline, twice daily on facial lines
- Early 10% emulsion: Reported 10% Argireline oil-in-water emulsion; amount per use not stated. twice daily, on the skin. Studied in a trial. Studied in: Healthy adult women. (source)
- Dry-skin cream: Fixed amount over the face; peptide strength and application mass not stated. every 12 hours, on the skin. Studied in a trial. Studied in: Women aged 40–57 with dry skin. (source)
- Oily-skin gel: Fixed amount over the face; peptide strength and application mass not stated. every 12 hours, on the skin. Studied in a trial. Studied in: Women aged 40–57 with oily skin. (source)
- Four-week eye-area trial: Argireline to the eye-area wrinkles; application amount not reported. twice daily, on the skin. Studied in a trial. Studied in: Chinese adults with peri-orbital wrinkles. (source)
- 0.005% eyelid study: 0.005% actual AH8 cream to eyelids; application mass not stated. twice daily, on the skin. Studied in a trial. Studied in: Adults with blepharospasm receiving toxin injections. (source)
- 0.025% eyelid study: 0.025% actual AH8 topical preparation; amount per use not reported. twice daily, on the skin. Studied in a trial. Studied in: Adults with primary blepharospasm. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Argireline
- Matrixyl: A topical cosmetic peptide with limited human evidence for making fine lines less visible.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Consumer products: cosmetics, Office for Product Safety and Standards · 2025
- HFP Centers of Excellence 2023-24 Annual Report, FDA · 2024
- Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice, FDA · 2004
- Allergens in Cosmetics, U.S. Food and Drug Administration · FDA
- Cosmetic ingredient database, European Commission
- Cosmetics, Therapeutic Goods Administration
- Microbiological Safety and Cosmetics, U.S. Food and Drug Administration · FDA
- Notification of Cosmetics, Health Canada
- Shelf Life and Expiration Dating of Cosmetics, FDA
- Wrinkle Treatments and Other Anti-aging Products, U.S. Food and Drug Administration
- DES-mediated self-assembled polypeptides: Synergistic neuromuscular signaling inhibition for anti-aging., Bai D et al. · Biomaterials advances · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.